FUNDAMENTALS |
MarketCap: |
26 709 mill
|
EPS: |
7.59
|
P/E: |
48.31
|
Earnings Date: |
Jul 25, 2024 |
SharesOutstanding: |
72.84 mill
|
Avg Daily Volume: |
0.527 mill
|
RATING
2024-05-08 |
A+
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Neutral
|
|
Return On Equity: |
Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Neutral
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
3.13x
|
Company: PE 48.31 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
1.14x
|
Company: PE 48.31 | industry: PE 42.42
|
DISCOUNTED CASH FLOW VALUE |
$161.80
(-55.87%)
$-204.86
|
Date: 2024-05-09
|
Expected Trading Range (DAY) |
$ 358.39 - 374.93
( +/- 2.26%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-04-23 | Pucci Paolo | Buy | 564 | Common Stock |
2024-04-23 | Michels Douglas A | Buy | 564 | Common Stock |
2024-04-23 | Lai Goldman Myla | Buy | 564 | Common Stock |
2024-04-23 | Lockhart Stephen H | Buy | 564 | Common Stock |
2024-04-23 | Keller Deborah L | Buy | 564 | Common Stock |
INSIDER POWER |
-9.45
|
Last
100 transactions |
Buy:
235 088 | Sell:
288 836 |
Forecast:
16:00 - $366.66
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $366.66
Forecast 2: 16:00 - $366.66
Forecast 3: 16:00 - $366.66
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$366.66 (-0.46% )
|
Volume |
0.284 mill
|
Avg. Vol. |
0.527 mill
|
% of Avg. Vol |
53.88 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For WST
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.